The use of PARP inhibitors has been approved for treatment in BRCA1 and BRCA2 mutated breast and ovarian cancers, and for therapy in platinum sensitive ovarian cancer patients with defective BRCA1/2 genes [74]. Here, BRCA2 is linked to ovarian cancer.